New oral antiplatelet agent ticagrelor approved in Korea

The Korea Food and Drug Administration said Thursday that it has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the rate of heart attack (myocardial infarction; MI) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS).

Ticagrelor, a new oral antiplatelet medicine, is indicated to reduce the rate of thrombotic cardiovascular events in patients with ACS (u...